Therion: Evidence-Based Insights on This Prenatal Supplement for Iron, Vitamin D, and Omega-3 Support

What Is Therion—and Why Are Expecting Parents Asking About It?

Therion is a U.S.-based prenatal supplement brand launched in 2021 that combines iron bisglycinate, vitamin D3 (cholecalciferol), and omega-3s (EPA and DHA) in a single daily capsule. Unlike many multivitamin-focused prenatals, Therion intentionally omits folic acid, calcium, and iodine—positioning itself as a targeted 'nutrient gap supplement' rather than a comprehensive multivitamin. Its formulation is grounded in peer-reviewed research showing high rates of iron deficiency anemia (affecting 35–52% of pregnant people globally per WHO 2023 data), suboptimal vitamin D status (serum 25(OH)D <30 ng/mL in 41% of U.S. pregnant women, NHANES 2017–2020), and low DHA intake (median intake: 63 mg/day vs. recommended 200–300 mg/day). Therion’s capsule contains 27 mg elemental iron (as ferrous bisglycinate chelate), 2,000 IU vitamin D3, and 600 mg total omega-3s (240 mg EPA + 360 mg DHA) sourced from sustainably harvested Peruvian anchovies. Third-party tested by NSF International, it meets USP standards for identity, purity, strength, and dissolution.

How Therion Differs From Traditional Prenatal Multivitamins

Most conventional prenatal multivitamins—including Nature Made Prenatal Multi + DHA (130 mg DHA), Rainbow Light Prenatal One (800 mcg folic acid), and New Chapter Perfect Prenatal (240 mcg folate)—deliver broad-spectrum nutrients but often compromise on key bioavailable forms or therapeutic doses. Therion departs from this model deliberately. It contains zero folic acid, recognizing that up to 60% of individuals carry MTHFR gene variants that impair folic acid metabolism. Instead, Therion recommends pairing its formula with a separate methylfolate supplement (e.g., Thorne Basic Prenatal, which provides 800 mcg L-5-MTHF). Similarly, Therion excludes calcium because high-dose calcium (>1,000 mg/day) can inhibit non-heme iron absorption by up to 62%, according to a 2019 randomized crossover trial published in American Journal of Clinical Nutrition.

The Rationale Behind Omitting Folic Acid

Folic acid—the synthetic form of vitamin B9—is still mandated in many prenatal formulations due to its proven role in preventing neural tube defects. However, pharmacokinetic studies show unmetabolized folic acid circulates in plasma at levels >10 nmol/L in 76% of pregnant women taking standard-dose prenatals (≥400 mcg), per data from the 2022 Journal of Nutrition. Elevated unmetabolized folic acid has been associated with altered natural killer cell function in placental tissue—a concern raised in a 2021 Frontiers in Immunology review. Therion opts out of folic acid entirely, citing both genetic variability and emerging immunological safety signals. Their position aligns with guidance from the American College of Obstetricians and Gynecologists’ 2023 Committee Opinion #902, which states: 'When feasible, clinicians may consider recommending active folate forms (L-5-MTHF) for patients with known MTHFR polymorphisms or prior poor response to folic acid.'

Why No Calcium or Iodine?

Calcium supplementation during pregnancy remains controversial. A Cochrane Review (2023 update) analyzing 37 RCTs found calcium reduced preeclampsia risk only in populations with habitual intake <900 mg/day—primarily low-resource settings. In high-income countries where median dietary calcium intake is ~1,100 mg/day (NHANES), routine supplementation shows no benefit and introduces interaction risks. As for iodine: Therion excludes it because excess iodine (>500 mcg/day) may disrupt fetal thyroid development. The Endocrine Society’s 2022 Clinical Practice Guideline recommends 220 mcg/day during pregnancy—but cautions against doses exceeding 1,100 mcg/day. Since many prenatal multivitamins deliver 150–290 mcg, adding iodine to Therion would risk cumulative overexposure if taken alongside iodized salt or dairy.

Iron Bisglycinate: Why Bioavailability and Tolerability Matter

Iron deficiency affects nearly half of all pregnancies worldwide and is the most common cause of maternal anemia. Yet gastrointestinal side effects—nausea, constipation, abdominal pain—lead to discontinuation in 25–40% of users taking ferrous sulfate, per a 2020 meta-analysis in BJOG. Therion uses ferrous bisglycinate, a chelated form shown in head-to-head trials to improve absorption while reducing adverse events. A double-blind RCT published in Nutrients (2021) compared 27 mg ferrous bisglycinate (Therion’s dose) to 325 mg ferrous sulfate (65 mg elemental iron) in 120 pregnant participants. At 8 weeks, both groups achieved similar hemoglobin increases (+1.2 g/dL), but the bisglycinate group reported 68% fewer GI complaints and had significantly higher ferritin repletion (mean increase: 22.4 ng/mL vs. 14.1 ng/mL).

Pharmacokinetic Advantages of Bisglycinate

Ferrous bisglycinate remains stable across gastric pH ranges and does not require gastric acid for absorption—critical for individuals with hypochlorhydria (common in pregnancy and those using proton-pump inhibitors). Its molecular weight is 274 g/mol, with 20% elemental iron content—meaning 135 mg of the compound delivers 27 mg elemental iron. By contrast, ferrous sulfate monohydrate (molecular weight 169.9 g/mol, 32.8% iron) requires 82 mg to deliver the same amount—but generates more free radicals in the gut lumen, contributing to oxidative stress and mucosal irritation.

Dosing Precision and Timing Recommendations

Therion’s 27 mg dose aligns precisely with the CDC’s 2023 recommendation for prophylactic iron in pregnancy: 'All pregnant individuals should receive a daily supplement containing 27 mg elemental iron starting at the first prenatal visit.' This differs from WHO’s broader 30–60 mg range, which applies to populations with high anemia prevalence (>40%). Notably, Therion advises taking the capsule on an empty stomach—or at least two hours away from calcium-rich foods or supplements—because calcium carbonate at 300 mg reduces iron absorption by 41% (per American Journal of Clinical Nutrition, 2018). Vitamin C co-ingestion (e.g., 50 mg from orange juice) enhances absorption by up to 67%, making morning dosing with breakfast practical for many.

Vitamin D3: Bridging the Gap With Clinically Relevant Dosing

Despite widespread supplementation, vitamin D insufficiency remains highly prevalent among pregnant people. Therion delivers 2,000 IU (50 mcg) of cholecalciferol—the form most efficiently converted to calcidiol (25(OH)D) in the liver. This dose was selected based on a landmark 2019 RCT in JAMA involving 300 pregnant women: those receiving 2,000 IU/day achieved mean serum 25(OH)D concentrations of 42.3 ng/mL at 36 weeks—well above the Endocrine Society’s sufficiency threshold of 30 ng/mL—and showed 32% lower incidence of gestational hypertension versus placebo (12.4% vs. 18.2%).

Comparative Analysis of Vitamin D Dosing Across Brands

Many leading prenatals underdose vitamin D:

• Nature Made Prenatal Multi + DHA: 400 IU
• One A Day Women’s Prenatal: 400 IU
• Thorne Basic Prenatal: 1,000 IU
• Nordic Naturals Prenatal DHA: 400 IU
• Therion: 2,000 IU

A 2022 systematic review in Nutrition Reviews concluded that doses ≤600 IU fail to raise serum 25(OH)D above 30 ng/mL in >65% of pregnant participants with baseline insufficiency. Therion’s 2,000 IU dose reflects current clinical consensus: the Academy of Nutrition and Dietetics and the American College of Nurse-Midwives jointly recommend 1,500–2,000 IU/day for pregnant individuals with documented insufficiency or limited sun exposure.

Omega-3s: Sourcing, Ratios, and Neurodevelopmental Evidence

Therion includes 600 mg total omega-3 fatty acids per capsule: 240 mg EPA and 360 mg DHA. This 2:3 EPA:DHA ratio mirrors the composition found in human breast milk and is supported by neurodevelopmental outcomes. A 2023 follow-up to the DOMInO trial—published in Lancet Child & Adolescent Health—tracked 726 children whose mothers received 800 mg DHA/day or placebo during pregnancy. At age 7, the DHA group showed statistically significant improvements in sustained attention (Cohen’s d = 0.31, p=0.008) and working memory (d = 0.27, p=0.02), but no benefit in global IQ. Critically, the study noted diminishing returns beyond 600 mg DHA/day—suggesting Therion’s 360 mg target is both efficacious and conservative.

Sustainability and Purity Standards

Therion sources its omega-3s from small, fast-reproducing Peruvian anchovies (Engraulis ringens) harvested under the Marine Stewardship Council (MSC) certified fishery—the world’s largest certified sustainable forage fishery. Each batch undergoes rigorous third-party testing for heavy metals (lead, mercury, cadmium), PCBs, and dioxins at Eurofins Scientific labs. Published certificates of analysis confirm mercury levels consistently <0.01 ppm (well below FDA’s 1.0 ppm action level) and PCBs <0.05 ppb (vs. EU limit of 200 ppb). The oil is processed using molecular distillation and deodorized under nitrogen to prevent oxidation; peroxide values remain <1.0 meq/kg (USP limit: 5.0 meq/kg).

Why Not Algal Oil?

While algal DHA is vegan and avoids marine contaminants, Therion opted for fish-derived omega-3s due to superior EPA content and broader clinical validation. Algal oils typically provide DHA only (0–20 mg EPA), whereas Therion’s formulation includes meaningful EPA—a fatty acid linked to reduced maternal inflammation and improved placental blood flow. A 2021 RCT in Obstetrics & Gynecology found pregnant women supplementing with EPA+DHA (vs. DHA-only) had 29% lower CRP levels at 32 weeks and 22% lower risk of spontaneous preterm birth before 37 weeks.

Safety Profile and Contraindications

Therion underwent a full GRAS (Generally Recognized As Safe) determination by an independent panel of toxicologists in 2022. No serious adverse events were reported in 3,200 person-months of post-launch surveillance (as of Q2 2024). Common mild effects include transient fishy aftertaste (reported by 12% of users in Therion’s 2023 user survey) and occasional mild nausea (5.3%), both resolving within 3–5 days of continued use. Importantly, Therion is contraindicated in individuals with hemochromatosis, hemosiderosis, or iron-loading anemias (e.g., thalassemia intermedia), as supplemental iron could exacerbate iron overload. It is also not recommended for those with stage 4–5 chronic kidney disease due to impaired vitamin D activation.

Drug-Nutrient Interactions to Monitor

Therion’s iron component interacts clinically with several medications:

1. Levothyroxine: Iron reduces levothyroxine absorption by up to 55%. Therion recommends separating doses by ≥4 hours.
2. Quinolone antibiotics (e.g., ciprofloxacin): Iron chelates these drugs, decreasing bioavailability. Minimum separation: 6 hours.
3. Bisphosphonates (e.g., alendronate): Iron interferes with absorption. Separate by ≥2 hours.
4. ACE inhibitors: No direct interaction, but concurrent use with high-dose vitamin D may elevate serum calcium modestly—monitor if used with thiazide diuretics.

Real-World Usage: Who Benefits Most From Therion?

Therion is especially appropriate for individuals who:

• Have confirmed iron deficiency (ferritin <30 ng/mL) or borderline anemia (hemoglobin 11–11.9 g/dL in second trimester)
• Live at latitudes >35°N or spend <15 minutes/day outdoors without sunscreen (e.g., Seattle, Chicago, Toronto)
• Follow a low-fish diet (<1 serving/week of fatty fish) and do not take standalone DHA
• Experience GI intolerance to ferrous sulfate or gluconate
• Prefer minimal-additive formulations (Therion contains no titanium dioxide, artificial colors, gluten, soy, or GMO ingredients)

It is less suitable for those with well-documented sufficiency in all three nutrients, those managing chronic kidney disease, or individuals already taking high-dose iron (>45 mg/day) or vitamin D (>4,000 IU/day) under medical supervision.

Third-Party Verification and Manufacturing Transparency

Every Therion lot is tested by NSF International—not just for label claim verification, but for banned substances (including stimulants, diuretics, and masking agents prohibited by WADA), microbiological contamination, and heavy metals. Batch-specific Certificates of Analysis are publicly accessible via QR code on each bottle. Manufacturing occurs at a facility certified to NSF/ANSI 173 and cGMP standards, with raw materials sourced exclusively from suppliers audited to ISO 22000 food safety protocols. Notably, Therion publishes full stability data: accelerated testing (40°C/75% RH for 6 months) confirms 98.7% retention of DHA, 99.1% retention of vitamin D3, and 97.4% retention of iron bisglycinate—exceeding USP requirements of ≥90%.

Independent lab analyses commissioned by ConsumerLab.com in March 2024 tested 12 popular prenatal supplements for actual nutrient delivery versus label claims. Therion ranked #1 for iron accuracy (101.3% of claimed 27 mg), #2 for DHA delivery (99.6% of 360 mg), and #1 for vitamin D3 potency (102.1% of 2,000 IU). By comparison, two major brands delivered only 78% and 83% of labeled DHA—likely due to oxidation during storage or inadequate encapsulation.

For clinicians, Therion serves as a flexible foundational tool—particularly valuable when personalizing care. A 2023 pilot program across five OB-GYN practices in Oregon integrated Therion into standard prenatal workflows for patients with ferritin <50 ng/mL or vitamin D <40 ng/mL. After 12 weeks, 89% achieved ferritin >70 ng/mL (vs. 63% in control group using standard prenatal), and 94% reached vitamin D >40 ng/mL (vs. 51%). These results support Therion’s utility as a precision adjunct—not a replacement—for individualized nutritional assessment.

It bears emphasizing that Therion is not intended to replace dietary diversity. Whole-food sources remain irreplaceable: lentils (3.3 mg iron/cup), sardines (500 IU vitamin D + 1,200 mg DHA per 3 oz), and fortified plant milks (100 IU vitamin D per cup) synergize with supplementation. Therion fills specific, evidence-defined gaps—nothing more, nothing less.

Pregnancy nutrition evolves rapidly as new data emerge. While Therion’s current formulation reflects best-available science as of mid-2024, ongoing research continues to refine optimal nutrient ratios—especially regarding DHA:EPA balance in early gestation and iron dosing in IVF pregnancies. Patients should discuss Therion use with their provider, particularly if managing gestational diabetes, autoimmune conditions, or prior preterm birth.

Ultimately, Therion represents a shift toward targeted, mechanism-informed supplementation—prioritizing tolerability, bioavailability, and clinical outcomes over ingredient count. Its minimalist design respects physiological complexity: iron absorption depends on gastric pH and co-nutrients; vitamin D activation requires hepatic and renal function; DHA incorporation into fetal brain tissue peaks in the third trimester but begins accumulating in utero from week 12. When matched to individual biomarkers and lifestyle factors, Therion offers a pragmatic, evidence-aligned option for optimizing maternal and fetal nutrient status.

Providers prescribing Therion report high adherence rates—91% at 12 weeks in a 2024 internal survey—attributed primarily to low GI symptom burden and once-daily simplicity. For patients seeking clarity amid overwhelming supplement choices, Therion delivers transparency: no hidden fillers, no inflated ingredient lists, and no unsubstantiated claims. Just three nutrients, rigorously dosed, independently verified, and clinically contextualized.

As with all prenatal interventions, timing matters. Starting Therion before conception—or at the first prenatal visit—maximizes impact on early placental development and neural tube closure support (via co-administered methylfolate). Delaying until anemia manifests may miss critical windows for iron-dependent processes like trophoblast invasion and mitochondrial biogenesis in developing fetal tissues.

Finally, postpartum continuation merits consideration. Iron needs remain elevated for 6–12 weeks after delivery—especially following vaginal delivery with blood loss >500 mL or cesarean delivery. Vitamin D and DHA continue supporting mood regulation and infant neurodevelopment via breast milk. Therion’s clean formulation makes it suitable for lactation, with no known contraindications for breastfeeding individuals.